Oncogenic RAS Induces a Distinctive Form of Non-Canonical Autophagy Mediated by the P38-ULK1-PI4KB Axis
Preprint
Abstract
SUMMARY: Cancer cells with RAS mutations exhibit enhanced autophagy, essential for their proliferation and survival, making it a potential target for therapeutic intervention. However, the regulatory differences between RAS-induced autophagy and physiological autophagy remain poorly understood, complicating the development of cancer-specific anti-autophagy treatments. In this study, we identified a form of non-canonical autophagy induced by oncogenic KRAS expression, termed RAS-induced non-canonical autophagy via ATG8ylation (RINCAA). RINCAA involves distinct autophagic factors compared to those in starvation-induced autophagy and incorporates non-autophagic components, resulting in the formation of non-canonical autophagosomes with multivesicular/multilaminar structures labeled by ATG8 family proteins (e.g., LC3 and GABARAP). We have designated these structures as RAS-induced multivesicular/multilaminar bodies of ATG8ylation (RIMMBA). A notable feature of RINCAA is the substitution of the class III PI3K in canonical autophagy for PI4KB. We identified a regulatory P38-ULK1-PI4KB-WIPI2 signaling cascade governing this process, where ULK1 phosphorylation at S317, S479, S556, and S758 activates PI4KB. This activation involves PI4KB phosphorylation at S256 and T263, initiating PI4P production, ATG8ylation, and non-canonical autophagy. Importantly, elevated PI4KB phosphorylation at S256 and T263 was observed in RAS-mutated cancer cells and colorectal cancer specimens. Inhibition of PI4KB S256 and T263 phosphorylation led to a reduction in RINCAA activity and tumor growth in both xenograft and KPC models of pancreatic cancer, suggesting that ULK1-mediated PI4KB-Peptide-1 phosphorylation could represent a promising therapeutic target for RAS-mutated cancers.Keywords
All Related Versions
- Published version: Cell Research, 35 (6), 399.
This publication has 119 references indexed in Scilit:
- Finding the sweet spot: Targeting RAS in tumors while sparing normal tissueCancer Cell, 2024
- The trilogy of P21 activated kinase, autophagy and immune evasion in pancreatic ductal adenocarcinomaCancer Letters, 2022
- Cancer cells escape autophagy inhibition via NRF2-induced macropinocytosisCancer Cell, 2021
- Molecular epidemiology and diagnostics of KRAS mutations in human cancerCancer and Metastasis Reviews, 2020
- Autophagy-Mediated Tumor PromotionCell, 2013
- The Hairpin-type Tail-Anchored SNARE Syntaxin 17 Targets to Autophagosomes for Fusion with Endosomes/LysosomesCell, 2012
- Autophagy and Self-Defense2012
- Autophagy in the Pathogenesis of DiseaseCell, 2008
- A Pharmacological Map of the PI3-K Family Defines a Role for p110α in Insulin SignalingCell, 2006
- Identification of a selective ERK inhibitor and structural determination of the inhibitor–ERK2 complexBiochemical and Biophysical Research Communications, 2005